Lista de obras -

A novel expression of macrophage derived chemokine in human bladder cancer

artículo científico publicado en 2005

An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines

artículo científico publicado en 1999

Animal Models of Urologic Chronic Pelvic Pain Syndromes: Findings From the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network

artículo científico publicado en 2015

Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.

artículo científico publicado en 2012

Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.

artículo científico publicado en 2014

Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?

artículo científico publicado en 2004

BCG immunotherapy of bladder cancer: 20 years on.

artículo científico publicado en 1999

BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation

artículo científico publicado en 2000

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

artículo científico publicado en 2003

Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.

artículo científico publicado en 2016

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease

artículo científico publicado en 2016

Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro

scientific article published on 01 June 1996

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

artículo científico publicado en 2010

Bladder Cancer Immunotherapy: BCG and Beyond.

artículo científico publicado en 2012

Bladder cancer: narrowing the gap between evidence and practice

artículo científico publicado en 2009

Can a point-of-care urine protein assay monitor bladder cancer recurrence?

scientific article published on 01 September 2006

Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant

artículo científico publicado en 2000

Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.

artículo científico

Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer

artículo científico publicado en 2018

Combination of BCG and interferon intravesical immunotherapy: an update.

artículo científico publicado en 2009

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.

artículo científico publicado en 2003

Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study

scientific article published on 15 May 2019

Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?

scientific article published on 10 April 2007

Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?

artículo científico publicado en 2006

Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer?

artículo científico publicado en 2008

Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells

artículo científico publicado en 2007

Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin

artículo científico publicado en 2006

Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy

artículo científico publicado en 2015

Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study.

artículo científico publicado en 2016

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

artículo científico publicado en 2015

Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ

artículo científico publicado en 2011

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

artículo científico publicado en 2006

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy

artículo científico publicado en 2008

Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs

artículo científico publicado en 2007

Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival

artículo científico publicado en 2016

Inflammation and Symptom Change in Interstitial Cystitis or Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study.

artículo científico publicado en 2016

Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms.

artículo científico publicado en 2014

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

artículo científico

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

artículo científico publicado en 2004

Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

artículo científico publicado en 2003

Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity

scientific article published on 01 March 2004

Interleukin-12. Opportunities for the treatment of bladder cancer.

artículo científico publicado en 2000

Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts

artículo científico publicado en 2015

Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.

artículo científico publicado en 1998

Intravesical colonic pseudotumor

artículo científico publicado en 2004

Intravesical treatments of bladder cancer: review.

artículo científico publicado en 2008

Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma.

artículo científico publicado en 2018

Management of stage T1 tumors of the bladder: International Consensus Panel.

artículo científico publicado en 2005

Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin

artículo científico publicado en 2002

Minimally invasive management of upper tract urothelial carcinoma.

artículo científico publicado en 2006

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer ⬇️

artículo científico publicado el 17 de marzo de 2013

Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo

artículo científico publicado en 2007

New imaging techniques for non-muscle invasive bladder cancer: ready for primetime

scientific article published on 07 March 2013

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer

artículo científico publicado en 2017

Optimizing BCG therapy

artículo científico publicado en 2009

Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment.

artículo científico publicado en 2005

Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study

artículo científico publicado en 2018

Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B ⬇️

artículo científico publicado el 1 de diciembre de 1997

Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder

artículo científico publicado en 2003

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer ⬇️

artículo científico publicado el 15 de marzo de 2013

Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer.

artículo científico publicado en 2005

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

artículo científico publicado en 2017

Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis ⬇️

artículo científico publicado el 1 de marzo de 1998

Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.

artículo científico publicado en 2017

Recognition and treatment of BCG failure in bladder cancer.

artículo científico publicado en 2011

Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

artículo científico publicado en 2004

Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity

artículo científico publicado en 2001

Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.

artículo científico publicado en 2007

Reply by the authors

Review of topical treatment of upper tract urothelial carcinoma.

artículo científico publicado en 2008

Risk-adapted use of intravesical immunotherapy.

artículo científico publicado en 2008

Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer

artículo científico publicado en 2012

Rubin H. Flocks and colloidal gold treatments for prostate cancer.

artículo científico publicado en 2011

Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.

artículo científico publicado en 2010

Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist ⬇️

artículo científico publicado el 1 de enero de 2011

Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study.

artículo científico publicado en 2018

Superficial bladder cancer: the role of interferon-alpha.

artículo científico publicado en 1998

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer

artículo científico publicado en 2018

Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

artículo científico publicado en 2011

The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.

artículo científico publicado en 2004

The genetic reconstruction of BCG as a new immunotherapeutic tool.

artículo científico publicado en 1997

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy

scientific article published on 01 May 2006

The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

artículo científico publicado en 2009

The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer

artículo científico publicado en 2008

Toll-like receptor 4 and comorbid pain in Interstitial Cystitis/Bladder Pain Syndrome: a multidisciplinary approach to the study of chronic pelvic pain research network study

artículo científico publicado en 2015

Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study

artículo científico publicado en 2016

Transitional cell carcinoma--tantalizing issues of tumor biology

artículo científico publicado en 1996

Treatment of Postoperative Ileus After Bowel Surgery with Low-Dose Intravenous Erythromycin

scientific article published on 01 April 2007

Treatment options for BCG failures.

artículo científico publicado en 2006

Treatment options in non-muscle-invasive bladder cancer after BCG failure

artículo científico publicado en 2015

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

artículo científico publicado en 2004

Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs.

artículo científico publicado en 2005

Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.

artículo científico publicado en 2004

Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.

artículo científico publicado en 2010

When medical evidence alone is simply not enough

artículo científico publicado en 2009

Lista de obras de

A novel expression of macrophage derived chemokine in human bladder cancer

An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines

Animal Models of Urologic Chronic Pelvic Pain Syndromes: Findings From the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network

Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.

Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.

Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?

BCG immunotherapy of bladder cancer: 20 years on.

BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease

Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

Bladder Cancer Immunotherapy: BCG and Beyond.

Bladder cancer: narrowing the gap between evidence and practice

Can a point-of-care urine protein assay monitor bladder cancer recurrence?

Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant

Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.

Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer

Combination of BCG and interferon intravesical immunotherapy: an update.

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.

Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study

Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?

Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?

Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer?

Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells

Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin

Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy

Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study.

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy

Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs

Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival

Inflammation and Symptom Change in Interstitial Cystitis or Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study.

Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity

Interleukin-12. Opportunities for the treatment of bladder cancer.

Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts

Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.

Intravesical colonic pseudotumor

Intravesical treatments of bladder cancer: review.

Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma.

Management of stage T1 tumors of the bladder: International Consensus Panel.

Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin

Minimally invasive management of upper tract urothelial carcinoma.

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer ⬇️

Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo

New imaging techniques for non-muscle invasive bladder cancer: ready for primetime

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer

Optimizing BCG therapy

Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment.

Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study

Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B ⬇️

Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer ⬇️

Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis ⬇️

Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.

Recognition and treatment of BCG failure in bladder cancer.

Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity

Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.

Reply by the authors

Review of topical treatment of upper tract urothelial carcinoma.

Risk-adapted use of intravesical immunotherapy.

Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer

Rubin H. Flocks and colloidal gold treatments for prostate cancer.

Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.

Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist ⬇️

Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study.

Superficial bladder cancer: the role of interferon-alpha.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer

Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.